Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment ; volume:13 ; number:3 ; day:15 ; month:6 ; year:2011 ; pages:1-9 ; date:6.2011
Breast cancer research ; 13, Heft 3 (15.6.2011), 1-9, 6.2011
- Urheber
-
Giuliano, Mario
- Beteiligte Personen und Organisationen
-
Giordano, Antonio
Jackson, Summer
Hess, Kenneth R.
De Giorgi, Ugo
Mego, Michal
Handy, Beverly C.
Ueno, Naoto T.
Álvarez, Ricardo H.
De Laurentiis, Michelino
De Placido, Sabino
Valero, Vicente
Hortobagyi, Gabriel N.
Reuben, James M.
Cristofanilli, Massimo
SpringerLink (Online service)
- DOI
-
10.1186/bcr2907
- URN
-
urn:nbn:de:1111-2016032411982
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
08.02.1125, 11:59 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Giuliano, Mario
- Giordano, Antonio
- Jackson, Summer
- Hess, Kenneth R.
- De Giorgi, Ugo
- Mego, Michal
- Handy, Beverly C.
- Ueno, Naoto T.
- Álvarez, Ricardo H.
- De Laurentiis, Michelino
- De Placido, Sabino
- Valero, Vicente
- Hortobagyi, Gabriel N.
- Reuben, James M.
- Cristofanilli, Massimo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prognostic potential of standard laboratory parameters in patients with metastatic renal cell cancer receiving first-line immunotherapy
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502
Prognostic potential of standard laboratory parameters in patients with metastatic renal cell cancer receiving first-line immunotherapy
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502
Prognostic potential of standard laboratory parameters in patients with metastatic renal cell cancer receiving first-line immunotherapy
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World